Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
April 29 2022 - 11:36AM
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on
discovering, developing and commercializing novel gene therapies,
biologicals and vaccines, today announced two presentations on the
company’s research into the development of a modifier gene therapy
to treat dry age-related macular degeneration (AMD), and a novel
biologic to treat wet-AMD and diabetic macular edema (DME) at The
Association for Research in Vision and Ophthalmology’s (ARVO) 2022
Annual Meeting in Denver on May 1 - 4, 2022.
“We are excited to share information about two of the innovative
treatments for blindness diseases we’ve been working on,” said Arun
Upadhyay, PhD, Ocugen’s Senior Vice President of Research &
Development. “Our breakthrough modifier gene therapy platform,
OCU410, consisting of a RORA modifier gene, has the potential to
treat patients with dry age-related macular degeneration (Dry-AMD).
RORA regulates inflammatory and oxidative pathways associated with
Dry-AMD and establishes homeostasis in molecular processes to
control the disease pathophysiology. We believe that OCU200, our
novel biologic product candidate, has the potential to offer a
better therapy to millions of people with diabetic macular edema,
diabetic retinopathy, and Wet-AMD, furthering our goal to provide a
new option for people who are currently underserved.”
Ocugen Presentations at ARVO 2022:
Presentation Title: OCU410, a Potential
Therapeutic for Dry-AMD, Suppresses Inflammatory Cytokine Gene
Expression in Retinal Pigment Epithelial
CellsAuthors: Dinesh K. Singh, Sree S. Kattala,
Arun K. UpadhyayPresentation Type: Poster Session
Presenter: Dinesh K. Singh, Principal Scientist,
DiscoveryDate/Time: May 1, 2022, from 12:15 – 2:15
PM MDT
Presentation Title: Binding
Affinity: A Measure of Potency for OCU200, a Potential Therapeutic
for the Treatment of Wet-AMD and DMEAuthors:
Pratap C. Naha, Subechhya Neupane, Arun K. Upadhyay.
Presentation Type: Oral
PresentationPresenter: Pratahap C. Naha, PhD,
Associate Director, Drug Delivery and Nanotechnology
Date/Time: May 4, 2022, at 3:00 PM MDT
About Dry Age-related Macular Degenerations (Dry
AMD)Age-related Macular Degeneration (AMD) is
characterized by thickening and loss of normal architecture within
Bruch’s membrane, lipofuscin accumulation in the retinal pigment
epithelium (“RPE”), and drusen formation beneath the RPE in Bruch’s
membrane. These deposits consist of complement components, other
inflammatory molecules, lipids, lipoproteins B and E, and
glycoproteins. Dry AMD, which affects about 9 to 10 million
Americans, involves the slow deterioration of the retina with
submacular drusen (small white or yellow dots on the retina),
atrophy, loss of macular function and central vision impairment.
Dry AMD accounts for 85-90% of the total AMD population, and there
is no approved treatment.
About Diabetic Macular Edema (DME and Diabetic
Retinopathy (DR) Diabetic macular edema (DME) and diabetic
retinopathy (DR) are the most common vision-threatening diseases
occurring in people with diabetes. Approximately 7.7 million people
are affected with DR and approximately 745,000 with DME in the
United States. These numbers are expected to further increase as
the number of people with diabetes increases.
About Wet-AMDAbout 10-15% of people with AMD
progress to the advanced “wet” form. It’s generally caused by
abnormal blood vessels that leak fluid or blood into the macula.
(The part of the retina that’s responsible for central vision.) The
result can be irreversible damage to photoreceptor cells and rapid,
severe vision loss, particularly in the center of the field of
vision, causing significant functional impairment. Wet-AMD accounts
for 90% of all AMD-related blindness.
About Ocugen, Inc. Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene therapies, biologicals and vaccines that
improve health and offer hope for people and global communities. We
are making an impact through courageous innovation, taking science
in new directions in service of patients. Our breakthrough modifier
gene therapy platform has the potential to treat multiple diseases
with one drug and we are advancing research in other therapeutic
areas to offer new options for people with unmet medical needs.
Discover more at www.ocugen.com and follow us on Twitter
and LinkedIn.
Cautionary Note on Forward-Looking Statements This press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995, which are subject
to risks and uncertainties. Such forward-looking statements within
this press release include, without limitation, the intended use of
net proceeds from the registered direct offering. We may, in some
cases, use terms such as “predicts,” “believes,” “potential,”
“proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from our
current expectations, such as market and other conditions. These
and other risks and uncertainties are more fully described in our
periodic filings with the Securities and Exchange Commission (the
“SEC”), including the risk factors described in the section
entitled “Risk Factors” in the quarterly and annual reports that we
file with the SEC. Any forward-looking statements that we make in
this press release speak only as of the date of this press release.
Except as required by law, we assume no obligation to update
forward-looking statements contained in this press release whether
as a result of new information, future events or otherwise, after
the date of this press release.
Ocugen Contact:Ken InchaustiHead, Investor
Relations & Communicationsken.inchausti@ocugen.com
Please submit investor-related inquiries to: IR@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024